Solute Carrier Family 26 Member 4 (SLC26A4), A Potential Therapeutic Target for Asthma
Journal of Respiratory Biology and Translational Medicine · 2024
DOI: 10.35534/jrbtm.2024.10011 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Respiratory Biology and Translational Medicine, 2024. Verfasst von Vineeta Guntupalli und 5 weiteren Autor:innen. Beteiligte Einrichtung: Division of Allergy and Clinical Immunology, Johns Hopkins University School of Medicine, Baltimore, MD 21224, USA. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 5 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAID NIH HHS.
Abstract (Originalsprache)
Asthma is a prevalent respiratory condition with multifaceted pathomechanisms, presenting challenges for therapeutic development. The SLC (Solute Carrier) gene family, encompassing diverse membrane transport proteins, plays pivotal roles in various human diseases by facilitating solute movement across biological membranes. These solutes include ions, sugars, amino acids, neurotransmitters, and drugs. Mutations in these ion channels have been associated with numerous disorders, underscoring the significance of SLC gene families in physiological processes. Among these, the SLC26A4 gene encodes pendrin, an anion exchange protein involved in transmembrane transport of chloride, iodide, and bicarbonate. Mutations in SLC26A4 are associated with Pendred syndrome. Elevated SLC26A4 expression has been linked to airway inflammation, hyperreactivity, and mucus production in asthma. Here, we review novel insights from SLC gene family members into the mechanisms of substrate transport and disease associations, with specific emphasis on SLC26A4. We explore triggers inducing SLC26A4 expression and its contributions to the pathogenesis of pulmonary diseases, particularly asthma. We summarize the inhibitors of SLC26A4 that have shown promise in the treatment of different phenotypes of diseases. While SLC26A4 inhibitors present potential treatments for asthma, further research is imperative to delineate their precise role in asthma pathogenesis and develop efficacious therapeutic strategies targeting this protein.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Allergy and Clinical Immunology, Johns Hopkins University School of Medicine, Baltimore, MD 21224, USA.
- Department of Respiratory and Critical Care Medicine, Xiangya Hospital, Central South University, Changsha 410008, China.
- Department of Respiratory Medicine, Children's Hospital of Soochow University, Suzhou 215000, China.
- Department of Otolaryngology Head and Neck Surgery, Xiangya Hospital of Central South University, Changsha 410008, China.
Förderung
- NIAID NIH HHS
Zitieren
APA
Guntupalli, V., Wan, R., Liu, L., Gu, W., Xie, S., & Gao, P. (2024). Solute Carrier Family 26 Member 4 (SLC26A4), A Potential Therapeutic Target for Asthma. Journal of Respiratory Biology and Translational Medicine. https://doi.org/10.35534/jrbtm.2024.10011
Vancouver
Guntupalli V, Wan R, Liu L, Gu W, Xie S, Gao P. Solute Carrier Family 26 Member 4 (SLC26A4), A Potential Therapeutic Target for Asthma. Journal of Respiratory Biology and Translational Medicine. 2024. doi:10.35534/jrbtm.2024.10011
BibTeX
@article{Guntupalli2024,
author = {Guntupalli, Vineeta and Wan, Rongjun and Liu, Liyuan and Gu, Wenjing and Xie, Shaobing and Gao, Peisong},
title = {Solute Carrier Family 26 Member 4 (SLC26A4), A Potential Therapeutic Target for Asthma},
journal = {Journal of Respiratory Biology and Translational Medicine},
year = {2024},
doi = {10.35534/jrbtm.2024.10011}
}
EUVIMED